Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Clinical Trial
Official title:
A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: - can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by patients. - will JNJ-90009530 help patients achieve a response and for how long?
| Status | Recruiting |
| Enrollment | 92 |
| Est. completion date | May 31, 2027 |
| Est. primary completion date | April 1, 2027 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Key Inclusion Criteria - Participant must be greater than or equal to (>=) 18 years of age, at the time of signing informed consent - All participants must have relapsed or refractory disease for each histologic subtype - Mature aggressive large B cell NHL and Follicular Lymphoma Grade 3b: Participants must have >= 2 lines of systemic therapy or >=1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). Participants also must have had exposure to an anthracycline and an anti-CD20 targeted agent - Follicular lymphoma Grade 1-3a and Marginal Zone Lymphoma: Participants must have >=2 prior lines of anti-neoplastic systemic therapy. Participants also must have prior exposure to an anti-CD20 monoclonal antibody - Tumor must be cluster of differentiation (CD) 20 positive - Measurable disease as defined by Lugano 2014 classification - Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 Key Exclusion Criteria - Diagnosis of Human herpes virus (HHV) 8-positive Diffuse large B Cell lymphoma (DLBCL) - Prior allogeneic Hematopoietic stem cell transplantation (HSCT) - Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T cell infusion - Uncontrolled active infections - History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis [DVT]) - History of stroke, unstable angina, myocardial infarction, congestive heart failure ( New York Heart Association [NYHA] Class III or IV), severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening - History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or neurodegenerative disorder - Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system - Active central nervous system (CNS) involvement by malignancy - Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones) |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Royal Prince Alfred Hospital | Camperdown | |
| Australia | Monash Medical Centre | Clayton | |
| Australia | Royal Brisbane and Women's Hospital | Herston | |
| Australia | Westmead Hospital | Westmead | |
| Israel | Hadassah Medical Center | Jerusalem | |
| Israel | Sheba Medical Center | Ramat Gan | |
| United States | University Hospitals Cleveland Medical Center | Cleveland | Ohio |
| United States | MD Anderson Cancer Center | Houston | Texas |
| United States | University of Iowa Hospital | Iowa City | Iowa |
| United States | University of Kentucky | Lexington | Kentucky |
| United States | Rutgers University | New Brunswick | New Jersey |
| Lead Sponsor | Collaborator |
|---|---|
| Janssen Research & Development, LLC |
United States, Australia, Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Calculate the Occurence of Adverse Events | The safety and tolerability will be measured by recording the occurence and severity of all adverse events or dose limiting toxicities that occur according to Common Terminology Criteria for Adverse Events (CTCAE) criteria version 5.0 | up to 24 months | |
| Primary | Determine Recommended Phase 2 dose (RP2D) | Employ a Bayesian optimal interval (BOIN) design and determine the RP2D with review of the number of dose-limiting toxicities | up to 24 months | |
| Secondary | Determine the Overall Response (OR) | Record the number of subjects who have a complete response (CR) or partial response (PR) by radiographical assessment using Lugano Criteria 2014 | up to 24 months | |
| Secondary | Determine the time to response (TTR) | Record the number of days from the date of JNJ-90009530 infusion to a CR or PR | up to 24 months | |
| Secondary | Determine the duration of response (DOR) | Record the number of days from the date of the first CR or PR to relapse or death. | up to 24 months | |
| Secondary | Measure the amount of JNJ-90009530 in blood over time | Review pharmacokinetics (PK) of JNJ-90009530 by measuring the Chimeric Antigen Receptor (CAR) copy number over time by Quantitative polymerase chain reaction (qPCR). | up to 24 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06173518 -
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
|
Phase 1 | |
| Recruiting |
NCT05421663 -
A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT02981745 -
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
|
Phase 1/Phase 2 |